Home / Community / News / News

News

08/15/2017 - 10:11am

Investigators at the University of California San Diego, the University of Florida, and the National University of Singapore have recently reported early research that potentially ‘repurposes’ gene editing technology for a set of RNA disorders—myotonic dystrophy type 1 (DM1), myotonic dystrophy type 2 (DM2), a subset of Lou Gehrig’s disease (ALS) patients and Huntington’s disease. They have modified the Cas9 enzyme so it is targeted to toxic RNA, instead of the expanded DNA repeats in these diseases.

07/06/2017 - 3:02pm

New fly models show a DM2 phenotype at least as severe as DM1 and may provide a platform for studies of genetic modifiers and candidate therapy screening in DM.

06/02/2017 - 4:29pm

A recent review article makes the case that DM is a brain disease and that better understanding of and treatment strategies for the neurological consequences of DM are essential.

06/02/2017 - 3:53pm

MDF staff recently attended the 2017 annual meeting of the American Academy of Neurology, in Boston, MA. Here are highlights from that meeting.

05/15/2017 - 2:54pm

MDF is also happy to help you understand whether something is in a legitimate clinical trial, an approved therapy…or not.

Partners

© Myotonic Dystrophy Foundation. All rights reserved.